Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo
Guifang Du(Chinese PLA General Hospital), Yinying Lu(Chinese PLA General Hospital)
Cited by 64
Related Papers
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
Characterization of Gut Microbiota, Bile Acid Metabolism, and Cytokines in Intrahepatic Cholangiocarcinoma
|Hepatology|2019|165
Two Things about COVID-19 Might Need Attention
|Preprints.org|2020|144
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
|Hepatology International|2023|60
Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.
|Journal of Clinical Oncology|2020|39